FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular, to an HLA-DR-binding antigen-binding molecule and to a composition containing T cells containing said molecule as a pharmaceutically effective ingredient.
EFFECT: invention is effective in treating cancer.
14 cl, 17 dwg, 2 tbl, 18 ex
Title | Year | Author | Number |
---|---|---|---|
ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
SPECIFIC TO MUCIN-1 POLYPEPTIDE AND ITS USE | 2021 |
|
RU2805840C1 |
PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
ANTIBODIES AGAINST TIGIT AND APPLICATION THEREOF | 2019 |
|
RU2750705C1 |
ANTIBODIES TO HUMAN INTERLEUKIN-2 AND THEIR APPLICATION | 2018 |
|
RU2745451C1 |
ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
ANTI-HUMAN 4-1BB ANTIBODIES AND USE THEREOF | 2018 |
|
RU2725811C1 |
ANTIBODIES AGAINST HUMAN 4-1BB AND THEIR USE | 2018 |
|
RU2777573C2 |
Authors
Dates
2022-08-29—Published
2019-08-12—Filed